Neuroscience
From Bloomberg:
Eli Lilly Shares Rise on Alzheimer’s Drug Hopes
By Drew Armstrong and Robert Langreth
Dec 6, 2011
[snip]
"Solanezumab is an antibody designed to clear protein fragments called beta amyloid that clutter the brains of patients with Alzheimer’s disease. Pfizer Inc. (PFE), Johnson & Johnson and Elan are testing bapineuzumab, a similar drug."
[snip]
Read the article
- Alzheimer: Clinical Trials Day At The Aaic2015 Conference
Alzheimer's Association Press Release at 0700 hrs EDT on 22 July 2015. - Longer-Term Analysis of Phase 3 Solanezumab (Lilly) Up to 3.5 Years - Biomarker Results from Phase 3 Gantenerumab (Roche) Trial - New Data from Aducanumab (Biogen) Phase 1b...
- Alzheimer's Disease
In Preventing Alzheimer’s, Mutation May Aid Drug Quest The New York Times By GINA KOLATA 11 July 2012 [snip] Two decades ago, researchers began discovering rare gene mutations that cause Alzheimer’s disease in all who inherit them. Now, they have...
- Alzheimer Disease: Dimebon Results, Part Ii
From The New York Times: Hopes for Alzheimer’s Drug Are Dashed By ANDREW POLLACK Published: March 4, 2010 "The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer’s and the companies developing...
- Reminyl (galantamine Hydrobromide) (continued)
Safety Concerns Reported on J.& J. Alzheimer's Drug By ANDREW POLLACK New York Times Published: January 22, 2005 Regulators are reviewing the safety of the Alzheimer's disease drug Reminyl after data from two clinical trials indicated...
- Reminyl (galantamine Hydrobromide)
From the New York Times: Johnson & Johnson Reports Reminyl Deaths By THE ASSOCIATED PRESS Published: January 21, 2005 Filed at 5:08 p.m. ET RARITAN, N.J. (AP) -- Patients taking Alzheimer's drug Reminyl in a test for another use had higher...
Neuroscience
Clinical Trials: Solanezumab in Alzheimer's Disease
From Bloomberg:
Eli Lilly Shares Rise on Alzheimer’s Drug Hopes
By Drew Armstrong and Robert Langreth
Dec 6, 2011
[snip]
"Solanezumab is an antibody designed to clear protein fragments called beta amyloid that clutter the brains of patients with Alzheimer’s disease. Pfizer Inc. (PFE), Johnson & Johnson and Elan are testing bapineuzumab, a similar drug."
[snip]
Read the article
- Alzheimer: Clinical Trials Day At The Aaic2015 Conference
Alzheimer's Association Press Release at 0700 hrs EDT on 22 July 2015. - Longer-Term Analysis of Phase 3 Solanezumab (Lilly) Up to 3.5 Years - Biomarker Results from Phase 3 Gantenerumab (Roche) Trial - New Data from Aducanumab (Biogen) Phase 1b...
- Alzheimer's Disease
In Preventing Alzheimer’s, Mutation May Aid Drug Quest The New York Times By GINA KOLATA 11 July 2012 [snip] Two decades ago, researchers began discovering rare gene mutations that cause Alzheimer’s disease in all who inherit them. Now, they have...
- Alzheimer Disease: Dimebon Results, Part Ii
From The New York Times: Hopes for Alzheimer’s Drug Are Dashed By ANDREW POLLACK Published: March 4, 2010 "The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer’s and the companies developing...
- Reminyl (galantamine Hydrobromide) (continued)
Safety Concerns Reported on J.& J. Alzheimer's Drug By ANDREW POLLACK New York Times Published: January 22, 2005 Regulators are reviewing the safety of the Alzheimer's disease drug Reminyl after data from two clinical trials indicated...
- Reminyl (galantamine Hydrobromide)
From the New York Times: Johnson & Johnson Reports Reminyl Deaths By THE ASSOCIATED PRESS Published: January 21, 2005 Filed at 5:08 p.m. ET RARITAN, N.J. (AP) -- Patients taking Alzheimer's drug Reminyl in a test for another use had higher...